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Abstract 
Rationale: Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human 
skeletal muscle cells. Variations of CFTR dysfunction among patients with CF may be an 
important determinant of maximal exercise capacity in CF. Previous studies on the relationship 
between CFTR genotype and maximal exercise capacity are scarce and contradictory.  
Objectives: This study was designed to explore factors influencing maximal exercise capacity, 
expressed as peak oxygen consumption (VO2peak), with a specific focus on CFTR genotype in 
children and adults with CF.  
Methods: In an international, multicenter cross-sectional study we collected data on CFTR 
genotype and cardiopulmonary exercise tests (CPET) in patients with CF eight years and older. 
CFTR mutations were classified into functional classes I-V.  
Results: The final analysis included 726 patients (45% females, age 8 to 61 years, FEV1 16 to 123 
% predicted) from 17 CF centers in North America, Europe, Australia and Asia whom all had 
both valid maximal CPET and complete CFTR genotype data. Overall, patients exhibited exercise 
intolerance (VO2peak, 77.3±19.1 % predicted), but values were comparable among different CFTR 
classes. We did not detect an association between CFTR genotype functional classes I-III and 
either VO2peak (% predicted) (adjusted β -0.95 (95% CI -4.18 to 2.29), P=0.57) or Wattsmax 
(adjusted β -1.38 (95% CI -5.04 to 2.27), P=0.46) compared to classes IV-V. Those with one copy 
of a class V mutation had a significantly lower VO2peak (β -10.64 % (95% CI -17.03 to -4.24), 
P<0.001) and lower Wattmax (adjusted β -9.95 % (95% CI -17.31 to -2.59) P=0.008) compared to 
those with two copies of a class II mutation. Using linear regression analysis adjusted for 
relevant confounders, lung function and body mass index were associated with VO2peak.  
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Conclusions: CFTR functional genotype class was not associated with maximal exercise capacity 
in patients with CF overall, but those with a single class V mutation had lower maximal exercise 
capacity. 
 
Abstract Word Count: 225 
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Cystic fibrosis (CF) is a disorder with autosomal recessive inheritance that ultimately leads to 
respiratory failure and premature death. The disease is caused by mutations in the Cystic 
Fibrosis Transmembrane Conductance Regulator (CFTR) gene coding for the CFTR protein that 
functions as an ion channel, mainly for chloride and bicarbonate (1). CFTR mutations are 
grouped into different classes based on their effect on CFTR protein production, trafficking, 
function and stability (1). CFTR is expressed in cell membranes of epithelial cells. It can also be 
found at the level of the sarcoplasmic reticulum in airway smooth muscle (2), human skeletal 
muscle cells (3, 4) and myocardium (5), but the precise physiological role of CFTR in these 
tissues is not fully understood (6). Previous studies suggest intrinsic functional abnormalities in 
skeletal muscles lacking functional CFTR (3, 4), possibly based on a disturbed calcium 
homeostasis in the muscle and increased systemic inflammation (3). It is therefore plausible 
that dysfunctional CFTR in human skeletal muscle could be a contributing factor to peripheral 
muscle weakness (7, 8) and reduced exercise capacity (e.g., peak oxygen uptake, VO2peak) in CF 
(8, 9). 
As VO2peak is a predictor of mortality in CF (10), the knowledge of important correlates of 
aerobic performance may help to guide patient care. Few, predominantly small, studies have 
previously investigated the relationships between CFTR genotype and VO2peak in patients with 
CF (11-14) with equivocal and controversial results. Selvadurai and colleagues (12) found that 
children with CF carrying a F508del gene mutation on one allele and a class I or class II CFTR 
mutation on the second allele had lower VO2peak (approximately 30-45%) and peak anaerobic 
exercise capacity (approximately 10-17%) compared to children with a class III, IV or V mutation 
on the second CFTR allele. However, this finding was based on univariate analysis in a relatively 
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small sample size and, thus, did not control for relevant determinants of exercise capacity such 
as nutritional status and chronic infection with Pseudomonas aeruginosa (8, 13, 15), which 
could have influenced their study findings and interpretation.  
The current study was designed to investigate factors associated with VO2peak (primary 
endpoint) and maximum work rate (Wattmax, secondary endpoint) with a specific focus on CFTR 
genotype in a large international cohort of children and adults with CF. We aimed to compare 
maximal exercise capacity among patients with CFTR mutations that result in severely reduced 
function (combinations of class I-III mutations) to patients with combinations of class IV-V 
mutations characterised by some residual CFTR function at the cell surface (16).  
 
Methods 
 
Study Design and Patients 
We invited members from the Exercise Working Group of the European Cystic Fibrosis Society 
to participate in the study. We also searched for publications in PubMed on exercise testing in 
CF to identify clinical studies in CF that included cardiopulmonary exercise testing (CPET). The 
CPET had to be performed on a cycle ergometer employing the Godfrey cycle protocol (17) or a 
modification thereof. Inclusion and exclusion criteria and detailed information on CPET can be 
found in the online supplement. 
We collected data on anthropometric characteristics, CF-related comorbidities (e.g., 
exocrine pancreatic insufficiency, CF-related diabetes (CFRD), colonisation with Pseudomonas 
aeruginosa), pulmonary function, CPET related data and genetic data. Chronic Pseudomonas 
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aeruginosa infection was considered to be present when >50% of at least four sputum samples 
collected in the previous year were positive (18). Spirometry was performed according to 
ATS/ERS standards (19). We calculated % predicted values for spirometry (20), VO2peak (21, 22), 
Wattmax (21, 23) and peak heart rate (24) as well as z-scores for body mass index (BMI) based on 
WHO criteria (25). Percent body fat was calculated using sex and age-specific prediction 
equations (26) and lean body mass was derived from body fat and weight. For the final models, 
VO2peak (primary endpoint) and Wattmax (secondary endpoint) were expressed as % predicted of 
reference values (22, 23). 
The classification of CFTR genotype (27, 28) was performed by a geneticist (SG) who was 
blinded to the exercise testing data. Details about the functional classification of CFTR alleles 
are shown in Table E1 of the online supplement. Study participants were grouped for the 
analysis of the primary endpoint (VO2peak in % predicted) in patients with both CFTR alleles in 
either class I, II or III (corresponding to severely reduced CFTR function) and patients with at 
least one mutant allele in class IV or class V (corresponding to some residual CFTR function) 
(16). In an exploratory analysis, we also compared maximal exercise capacity between patients 
with at least one copy of the F508del mutation and categorised them into five groups based on 
their second CFTR mutation class (11, 27).  
Ethical approval for this study was obtained from the cantonal ethical committee of 
Zurich, Switzerland (2015-0109). All centers obtained ethical approval (if required) for the use 
of their anonymized patient data according to national and local policies. 
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Statistical Analysis 
Details on the statistical analyses can be found in the online supplement. We used analysis of 
variance, Kruskal-Wallis tests, and χ
2
 tests to compare variables between groups. We used 
mixed effects models with a random intercept for study center to identify characteristics 
associated with VO2peak and Wattmax (% predicted). Multilevel mixed-effects models with a 
random intercept for each study center were used to examine associations between CFTR 
genotype-based group and VO2peak and Wattmax (% predicted). The models were a priori 
adjusted for the variables age, sex, BMI z-score and FEV1 (% predicted) because it is generally 
accepted that they have an influence on VO2peak (9, 29, 30). Following the results of van de 
Weert-van Leeuwen (13), chronic infection with Pseudomonas aeruginosa is associated with 
decline in VO2peak over time and therefore represents and important covariate in our model. In 
order to decide if the potential confounders cystic fibrosis-related diabetes (CFRD) or 
pancreatic insufficiency should be taken into account, Akaike’s information criterion (AIC) was 
used for model choice. However, the models did not improve when adding those variables, for 
which reason they were discarded. We also checked if interactions between CFTR genotype-
based group and the other influential variables improved the models, which was not the case.   
To confirm our approach of defining the exercise capacity outcome variables as % 
predicted values, we additionally performed linear mixed-models using a multiplicative, 
allometric approach to account for potential effects of body size and pulmonary function on the 
relationship between CFTR genotype and VO2peak (see online supplement). 
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Results 
 
We contacted 32 centers in North America, Europe, Australia and Asia by email of which 17 
provided data for this study. Reasons for non-participation can be found in the online 
supplements. Included centers were from Canada (N=3,293 patients), US (N=2, 110 patients) 
and one centre each from Austria (N=30), Australia (N=30), France (N=59), Germany (N=69), 
Greece (N=39), Israel (N=37), Italy (N=34), Netherlands (N=93), Spain (N=51), Serbia (N=64), 
Switzerland (N=42), and the UK (N=39). A flow chart of included patients is shown in Figure 1 
and patient characteristics are shown in Table 1. 112 of 838 patients did not reach their 
maximal exercise level during the CPET and were excluded from further analyses. Criteria for a 
maximal effort during CPET are provided in the online supplement. These 112 patients were on 
average older, had lower FEV1, lower exercise capacity and more CF-related comorbidities 
(Table 1). The lower exercise capacity in patients not performing maximally was not explained 
by a pulmonary function limitation (i.e., a lower breathing reserve at end-exercise 
(VEpeak/MVVpred)) compared to the group demonstrating maximal effort (Table 1). The final 
dataset included 726 patients [(45% females, age 18.7±8.5 years (range 8 to 61), FEV1 76.6±22.9 
(range 16 to 123), VO2peak 77.3±19.1 % predicted (range 25 to 137)]. Figure 1 in the online 
supplements shows the relationship between FEV1 and VO2peak. Table 2 shows data for maximal 
exercise capacity, lung function, nutritional status and CPET-related variables grouped by CFTR 
class.  
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Predictors of Maximal Exercise Capacity in Patients with CF 
In the univariate analysis adjusted for study center we did not find any association of CFTR 
functional class (I-III versus IV-V) with either VO2peak % predicted (β 0.25 (95% CI -1.27 to 6.35), 
P=0.19) or Wattmax % predicted (β 2.34 (95% CI 1.90 to 6.58), P=0.28). In contrast, age, FEV1 % 
predicted, BMI z-score, CFRD and chronic Pseudomonas aeruginosa infection were associated 
with VO2peak and Wattmax (expressed as % predicted). Exocrine pancreatic insufficiency was only 
associated with Wattmax (% predicted). FVC was not included in the final multilevel multivariate 
model due to a high collinearity with FEV1 (R=0.89, P=0.001). We noted differences in VO2peak 
and Wattmax among study centers. Consequently, center was included as random intercept in 
the multilevel mixed-effects models. In fully adjusted models, FEV1 % predicted (β 0.41 (95% CI 
0.36 to 0.47), P<0.001) and BMI z-score (β 1.75 (95% CI 0.76 to 2.74), P=0.001) were 
significantly associated with VO2peak (% predicted). In the model for Wattmax (% predicted), FEV1 
% predicted (β 0.46 (95% CI 0.40 to 0.52), P<0.001) and BMI z-score (β 1.27 (95% CI 0.15 to 
2.38), P=0.03) remained the only significant predictors. 
  
Associations of CFTR Functional Class and Maximal Exercise Capacity  
The prevalences of CFRD, pancreatic insufficiency and Pseudomonas aeruginosa infection were 
higher for patients with only class I-III CFTR mutations compared to patients with at least one 
CFTR allele associated with residual function (class IV or class V). Univariate analysis revealed no 
differences in maximal exercise capacity (absolute and % predicted VO2peak and Wattmax) 
between the two groups (Table 3). In mixed-effects models, we did not detect an association 
between CFTR genotype functional class and either VO2peak (% predicted) (β -0.95 (95% CI -4.18 
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to - 2.29), P=0.57) or Wattsmax (β -1.38 (95% CI -5.04 to - 2.27), P=0.46). In these models, both 
lung function and nutritional status were associated with VO2peak and Wattmax (% predicted) 
independent of CFTR function (Table 4). These results were confirmed when allometric 
modelling was applied (Table E2) and when exercise capacity was expressed per kilogram body 
weight or lean body mass (data not shown). Moreover, the results were similar when the 112 
patients with non-maximal CPET’s were included in the analysis. In 835 and 831 patients, we 
found no association between CFTR genotype functional class and either VO2peak (% predicted) 
(β -1.95 (95% CI -5.28 to 1.39), P=0.25) or Wattsmax (β -2.42 (95% CI -5.97 to 1.48), P=0.24), 
respectively. 
 In a subanalysis restricted to patients with preserved lung function (FEV1 ≥ 80% 
predicted) and nutritional status (BMI z-score ≥ 50
th
 percentile), we found no between-group 
differences in maximal exercise capacity in either univariate or adjusted analysis (Table E3 and 
E4). Further, a subanalysis on patients with moderate to severe lung function impairment (FEV1 
≤ 60% predicted) did not show between-group differences in either VO2peak or Wattmax (% 
predicted, Table E5 and E6).  
 
Exercise Capacity among Patients with at Least One Copy of the F508del-CFTR Mutation 
In 653 patients who had at least one copy of the F508del-CFTR (class II) mutation grouped in 
five classes according to their second allele, no differences among CFTR genotype and either 
VO2peak or Wattmax were observed (absolute values or % predicted, see Table E7). In mixed 
models, patients with one copy of a class V mutation had a significantly lower VO2peak compared 
to patients with two copies of a class II mutation (β -10.64 % (95% CI -17.03 to -4.24), P<0.001, 
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see Table E8). Furthermore, Wattmax values were lower for the group with one copy of a class V 
mutation (β -9.95 % (95% CI -17.31 to -2.59) P=0.008). In addition, the same association was 
found for (31) VO2peak and (31) Wattmax using allometric models (Table E9). 
 
Discussion 
 
In this largest international multicentre study of exercise testing in CF patients to date we 
primarily focused on the relationship between CFTR genotype and predictors of maximal 
exercise capacity in patients with CF. We found that severity of CFTR genotype, using different 
CFTR categorisations, combinations, and analytic approaches, was not associated with maximal 
exercise capacity. In contrast, pulmonary function and nutritional status, expressed as BMI, 
were strongly associated with exercise capacity. 
Our data do not support a relevant role of CFTR genotype on maximal exercise capacity 
in patients with CF. However, some theoretical considerations deserve further explanation to 
shed light on potential underlying molecular mechanisms of the CFTR defect and its potential 
consequences on peripheral muscle function and exercise capacity. Recently, the expression of 
functional CFTR channels in human skeletal muscle was demonstrated (3, 4). Lamhonwah and 
colleagues (4) speculated that a dysfunction in sarcoplasmic reticulum CFTR channels might 
affect calcium release and thus impact the ATP-mediated actin-myosin interaction that is 
essential for muscle contraction. Moreover, Divangahi et al. (3) suggested that excessive 
systemic inflammation initiates a process in which the abnormal vulnerability of CFTR-deficient 
muscle to pro-inflammatory mediators could play a key role in the development of skeletal 
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muscle weakness observed in individuals with CF (7). Of note, these observations are based on 
animal experiments and have not yet been confirmed in humans. Based on the in vitro 
experiments, suggesting that systemic inflammation in combination with CFTR dysfunction may 
impair skeletal muscle function, it is reasonable to speculate that potential detrimental effects 
of CFTR genotype on aerobic exercise capacity would only be detected with high levels of 
inflammation. However, while the current study included patients with mildly impaired 
pulmonary function (mean±SD FEV1 77.3±23 % predicted), a subgroup analysis including only 
patients with moderate-to-severe lung disease (FEV1 ≤ 60% predicted) yielded similar results for 
the comparison between minimal-function and residual function mutations (Tables E5, E6). 
However, this subanalysis is limited by the small sample size of patients with residual function 
mutations and should be interpreted with caution. It remains to be shown in larger (ideally 
prospective) studies, whether our findings are applicable to patients with more advanced 
disease and substantial inflammation.  
Our main aim was to compare maximal exercise capacity between patients with CF 
carrying only minimal function CFTR mutations (classes I-III) and those with at least one residual 
function (class IV or V) CFTR mutation. In the primary analysis, our data showed no differences 
in maximal exercise capacity between groups in both unadjusted and adjusted analyses. These 
results were confirmed by the use of allometric models that were computed to exclude 
potential limitations of the prediction equations for VO2peak and Wattmax (32). Irrespective of the 
analytic approach – including adjustments for important confounders – we found robust 
evidence that CFTR genotype severity was not related to impaired maximal exercise capacity in 
patients with CF.  
Page 13 of 44  ANNALSATS Articles in Press. Published on 15-November-2017 as 10.1513/AnnalsATS.201707-570OC 
 Copyright © 2017 by the American Thoracic Society 
Co
py
rig
ht
© 
20
17
 Am
eri
ca
n T
ho
rac
ic 
So
cie
ty
   
Our findings support previous studies showing that pulmonary function limitation and 
inadequate nutrition contribute to exercise intolerance in patients with CF (9, 13, 29, 30, 33, 
34). Nutritional status plays a critical role in the progression of lung disease. Compared to 
healthy subjects, patients with CF exhibit peripheral muscle weakness (35) that is associated 
with reduced aerobic exercise capacity (7, 8). Thus, adequate nutrition and maintenance of 
BMI, and in particular muscle mass (35), is important for preserving exercise tolerance in 
patients with CF. The strong impact of lung function and nutritional status could mask the effect 
of CFTR genotype on exercise capacity in patients with CF. Consequently, to exclusively study 
the role of CFTR genotype on exercise capacity, we performed a sub analysis restricted to 
patients with preserved lung function (FEV1 ≥ 80% predicted) and nutritional status (BMI z-
score ≥ 50
th
 percentile) and results remained qualitatively the same.  
Our data are in contrast to a study by Selvadurai et al. (12) reporting a relationship 
between the severity of CFTR functional impairment and reduced exercise capacity using 
univariate analysis in children with CF aged 8-17 years with at least one copy of the F508del-
CFTR mutation. In univariate analysis, we noticed no differences between groups in either 
absolute or % predicted values for VO2peak or Wattmax (Table E6). However, in the adjusted 
analysis, patients with one copy of a class V mutation had significantly lower exercise capacity 
(about 8% predicted for both VO2peak and Wattmax) compared to patients homozygous for the 
F508del-CFTR mutation (Table E7, E8). Patients with one copy of a class V mutation did not 
differ in ethnicity and lung function but had better nutritional status compared to patients 
homozygous for the F508del-CFTR mutation. However, there was no evidence for ventilatory 
limitation (i.e., lower breathing reserve) during exercise in these patients, which may suggest 
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that the lower exercise performance was more reflective of fitness level rather than a reflection 
of their pulmonary status. Moreover, in mixed models, presence of Pseudomonas aeruginosa 
infection was significantly associated with a lower VO2peak and Wattmax (Table E8). This is 
supported by a study from van de Weert-van Leeuwen et al. (13) who have previously shown 
that presence of Pseudomonas aeruginosa in adolescents with CF is a predictor of a steeper 
decline in VO2peak over time, independent of age, nutritional status, pulmonary function and 
immunoglobulin G levels. Nevertheless, relatively fewer patients with a group V mutation were 
colonised with Pseudomonas aeruginosa than patients with solely CFTR class II mutations 
(reference group) despite a lower VO2peak in the former compared to the latter group. The 
differences between our study and the study by Selvadurai et al. (12) might be explained by the 
preserved lung function in the present cohort of patients and our rigorous adjustment for 
important clinical confounders in the statistical models. In addition, substantial CFTR 
misclassification affecting different groups in the study by Selvadurai et al. (12) may contribute 
to the diverse findings. Finally, we can only speculate that lower habitual physical activity, a 
determinant of VO2peak in CF (9), contributes to the reduced exercise capacity in patients with 
one copy of a class V mutation. The cohort of patients with class IV or V CFTR mutations in our 
study might be a subgroup of patients that have been diagnosed at older ages, i.e., when their 
CF disease progressed and started to become symptomatic. Thus, later CF diagnosis and less 
focus clinically on exercise and physical activity may affect behaviour in early childhood for a 
less active lifestyle.    
It is important to note that VO2peak shows a large variation across the population, and 
available prediction equations have their limitations. Most of the equations that are used in CF 
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research were established several decades ago, and mostly on small study samples that do not 
cover the whole age range of our population and/or do not consider both sexes (21, 22, 36). We 
decided to use VO2peak prediction equations published by Orenstein et al. (22) as these 
equations were shown to be related with health-related quality of life (37), patient-reported 
health status (38) and mortality (10) in patients with CF. In addition, we tested another 
frequently used prediction equation for VO2peak (21) and the results of all models were 
comparable to the prediction equation by Orenstein et al. (22). However, when using equations 
from Jones et al. [21], we noticed significant associations between VO2peak (and Wattmax in % 
predicted) with age and sex in the adjusted random effects models, which raises concern about 
the validity of these equations for this specific CF population.  
This study has several limitations. First, we collected data from different international 
study centers. Thus, we cannot rule out differences in treatment strategies and treatment quality 
possibly affecting the health status of the patients thereby introducing bias. Second, the groups 
classified according to CFTR classes were unevenly distributed with a high number of patients in 
the group with the most common F508del-CFTR mutation (39, 40), compared to patients carrying 
a CFTR class I, III, IV or V mutation. Despite the large sample size of 726 patients from 17 
different CF centers worldwide, group sizes with CFTR class I and III-V mutations were relatively 
small due to the generally low prevalence of these gene mutations (41). For these reasons, the 
exploratory analysis comparing exercise capacity among patients with at least one copy of the 
F508del-CFTR mutation should be interpreted with caution. Moreover, we were not able to 
consider all known confounders impacting exercise capacity such as physical activity (9), 
inflammatory markers and other CF airway pathogens that were either not routinely assessed or 
Page 16 of 44 ANNALSATS Articles in Press. Published on 15-November-2017 as 10.1513/AnnalsATS.201707-570OC 
 Copyright © 2017 by the American Thoracic Society 
Co
py
rig
ht
© 
20
17
 Am
eri
ca
n T
ho
rac
ic 
So
cie
ty
   
not available for this retrospective analysis. Nevertheless, strong predictors of VO2peak such as 
pulmonary function (9, 13, 29, 30, 33) and nutritional status (34) as well as proxy measures of 
inflammation (i.e., Pseudomonas aeruginosa status), were included in our statistical analysis. In 
addition, our analysis was limited to maximal CPET outcomes. Additional measures such as VO2 
at the anaerobic threshold would have provided further insights into muscle (dys-)function. 
Finally, we acknowledge the limitation of the retrospective study design and the collection of 
data over a large time period. However, it seems practically impossible to acquire such a large 
dataset on CPET variables within a prospective study that would overcome these limitations.  
In summary, in our large, international cohort of children, adolescents and adults with 
CF, we did not detect an association between CFTR genotype group and maximal exercise 
capacity. In this cohort, lower pulmonary function and worse nutritional status were associated 
with reduced exercise capacity. These findings underline the importance of preserving lung 
function and maintaining adequate nutrition to prevent exercise intolerance in patients with 
CF. 
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Figure Legend: 
 
Figure 1. Flow chart of included patients. CFTR, cystic fibrosis transmembrane conductance 
regulator; CPET, cardiopulmonary exercise test.  
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Table 1. Clinical characteristics and cardiopulmonary exercise testing data for patients with 
valid versus non-valid maximal exercise tests. 
 
 
Variable N Valid maximal CPET N Non-valid maximal 
CPET 
Age (years)
†
 726 16.4 (13.0, 22.1) 112 20.9 (13.9, 28.8) 
Sex (% females) 726 330 (45) 112 45 (40) 
BMI z-score
*
 726 -0.24 (-0.92, 0.47)  112 -0.01 (-0.75, 0.70) 
FEV1 (% predicted)
*
 724 79 (66, 91) 111 74 (56, 86) 
CFRD (N, %)
*
 723 79 (11) 109 20 (18) 
Pseudomonas aeruginosa (N, %)
†
 716 371 (52) 105 83 (79) 
Pancreatic insufficiency (N, %) 724 611 (84) 112 90 (80) 
VO2peak (% predicted)
†
 
Orenstein
 726 79 ± 19 112 67 ± 15 
VO2peak (% predicted)
† Orenstein/Jones
 726 80 ± 20 112 70 ± 15 
Wattmax (% predicted)
† Godfrey
  724 85 ± 22 112 74 ± 18 
Wattmax (% predicted)
† Godfrey/Jones
 724 91 ± 23 112 82 ± 19 
HRpeak (% predicted)
†
 725 93 (88, 96) 112 87 (80, 92) 
RER
†
 639
‡
 1.16 (1.10, 1.23) 36
‡
 0.99 (0.96, 1.01) 
VEpeak/MVVpred
†
 725 86 (70, 102) 111 76 (63, 87) 
Data are mean±SD or median (interquartile range) or N (%). BMI; body mass index; CFRD, Cystic 
fibrosis related diabetes; CPET, cardiopulmonary exercise test; FEV1, forced expiratory volume 
in one second; RER, respiratory exchange ratio; VO2peak, peak oxygen consumption; Wattmax, 
maximum work rate. Percent predicted values for VO2peak were calculated using equations from 
Orenstein et al. (22) and Jones et al. (21). Data for VO2peak are shown separately according to 
Orenstein et al. (22) and a combination of Orenstein et al. (22) and Jones et al. [21] for patients 
aged ≤16 and >16 years, respectively. Wattmax % predicted values were calculated using 
equations from Godfrey et al. (23) and Jones et al. (21). Data are shown separately according to 
Godfrey et al. (23) and a combination of Godfrey et al. (23) and Jones et al. [21] for patients 
aged ≤ 16 and >16 years, respectively. Statistical comparisons between groups were performed 
using ANOVA or the non-parametric Mann-Whitney U test or the χ
2
 test as appropriate. 
* 
P<0.05; 
† 
P<0.001; 
‡ 
RER data were not available from two study centers.  
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Table 2. Lung function, nutritional status and exercise capacity in 726 patients according to CFTR mutation (functional classes I-V) 
based on the functional defect of the milder of the two mutations. 
 
 CFTR class I/I CFTR class ≤ II/II CFTR class ≤ III/III CFTR class ≤ IV/IV CFTR class ≤ V/V 
N 32 550 39 63 42 
Age
*
 14.6 (12.7, 18.3) 16.2 (12.9, 21.3) 16.7 (12.1, 25.0) 16.6 (12.1, 25.0) 19.0 (14.8, 26.5) 
Sex (% female) 14 (44) 244 (44) 16 (41) 34 (54) 21 (50) 
CFRD, (N, %)
*
 7 (22) 64 (12)  4 (10) 2 (3) 1 (2) 
Pancreatic insufficiency (N, %)
†
 35 (97)
 
 529 (93)
 
 34 (89)
 
 15 (24) 10 (24) 
Pseudomonas aeruginosa (N, %)
*
 32 (100) 519 (95) 21 (55) 23 (37) 15 (36) 
BMI (kg.m
-2
)
†
 18.8 (16.9, 20.1) 19.3 (17.3, 21.5) 20.4 (17.5, 24.2) 20.6 (18.8, 23.0) 22.3 (19.2, 25.0) 
BMI z-score
*
 -0.35 (-1.05, 0.39) -0.28 (-0.97, 0.35)  0.26 (-0.53, 1.04) -0.20 (-0.76, 0.63) 0.08 (-0.79, 1.14) 
Lean body mass (kg)
*
 38.2 (30.0, 46.4) 41.3 (32.9, 50.3) 43.5 (32.1, 55.2) 42.3 (36.7, 52.8) 47.0 (40.4, 61.1) 
Body fat (%)
†
 17.2 ± 4.7 18.2 ± 5.7 19.9 ± 5.5 21.4 ± 6.4 22.4 ± 6.5 
FEV1 (% predicted) 80 (45, 93) 79 (60, 94) 78 (50, 90) 86 (72, 96) 80 (62, 94) 
VO2peak (L.min
-1
) 1.6 (1.3, 1.8) 1.7 (1.4, 2.3) 1.8 (1.3, 2.2) 1.8 (1.5, 2.3) 1.7 (1.3, 2.4) 
VO2peak (% predicted) 
Orenstein
 74 ± 17 79 ± 19 78 ± 24 83 ± 18 74 ± 19 
VO2peak (% predicted) 
Orenstein/Jones
 74 ± 17 80 ± 19 79 ± 23 85 ± 18 78 ± 23 
VO2peak <82 % predicted (N, %) 21 (66) 313 (57) 23 (59) 32 (51) 28 (67) 
Wattmax (W) 111 (83, 140) 127 (98, 170) 130 (95, 163) 124 (95, 170) 130 (85, 180) 
Wattmax (% predicted) 
Godfrey
 77 ± 17 86 ± 22 85 ± 25  86 ± 21 78 ± 20 
Wattmax (% predicted)
*
 
Godfrey/Jones
 79 ± 18 92 ± 24 91 ± 27 92 ± 22 87 ± 20 
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Wattmax <93 % predicted (N, %) 27 (84) 358 (65) 23 (59) 44 (70) 31 (74) 
HRmax (% predicted) 92 (86, 96) 93 (88, 97) 91 (87, 97) 92 (87, 96) 92 (86, 96) 
RER 1.18 (1.12, 1.25) 1.16 (1.10, 1.23) 1.16 (1.11, 1.24) 1.14 (1.09, 1.20) 1.17 (1.08, 1.23) 
VEpeak/MVVpred (%)
*
 81 (72, 106) 88 (71, 103) 95 (72, 118) 75 (64, 92) 80 (61, 101) 
 
Data are mean±SD or median (interquartile range) or N (%). BMI; body mass index; CFRD, Cystic fibrosis related diabetes; FEV1, 
forced expiratory volume in one second; HRmax, maximum heart rate; MVVpred, predicted maximum voluntary ventilation (calculated 
as FEV1*35); RER, respiratory exchange ratio; VEpeak, peak minute ventilation; VO2peak, peak oxygen consumption; Wattmax, maximum 
work rate. Percent predicted values for VO2peak were calculated using equations from Orenstein et al. (22) and Jones et al. (21). Data 
for VO2peak are shown separately according to Orenstein et al. (22) and a combination of Orenstein et al. (22) and Jones et al. (21) for 
patients aged ≤16 and >16 years, respectively. Wattmax % predicted values were calculated using equations from Godfrey et al. (23) 
and Jones et al. (21). Data are shown separately according to Godfrey et al. (23) and a combination of Godfrey et al. (23) and Jones 
et al. (21) for patients aged ≤ 16 and >16 years, respectively. Reduced exercise capacity (VO2peak <82%pred and Wattmax <93%pred) 
according to Nixon et al. (10). Statistical comparisons between different CFTR classes were performed using ANOVA or the non-
parametric Kruskal-Wallis test or χ
2
 test for categorical variables. 
*
P<0.05, 
†
P<0.001 significantly different between CFTR classes. 
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Table 3. Clinical characteristics and cardiopulmonary exercise testing data between patients 
with two CFTR mutations in class I, II or III compared with patients with at least one mutation in 
class IV or V.  
 
Variable CFTR classes I-III CFTR classes IV-V 
N 621 105 
CFTR modulator therapy (N, %) 9 (1) 3 (3) 
Age 16.2 (12.9, 21.6) 18.0 (13.0, 25.5) 
Sex, (% female) 273 (44) 55 (52) 
CFRD, (N, %)
*
 75 (12) 3 (3) 
Pancreatic insufficiency, (N, %)
*
 585 (95) 25 (24) 
Pseudomonas aeruginosa, (N, %)
†
 332 (54) 38 (36) 
BMI z-score
*
  -0.25 (-0.95, 0.42) -0.11 (-0.77, 0.74) 
Body fat (%)
†
 18.2 ± 5.7 21.8 ± 6.4 
Lean body mass (kg) 41.1 (32.5, 50.3) 44.1 (36.4, 54.0) 
FEV1 (% predicted) 79 (59, 93) 84 (68, 96) 
VO2peak (L. min
-1
) 1.74 (1.4, 2.2) 1.78 (1.4, 2.4) 
VO2peak (% predicted) 
Orenstein
 79 ± 19  80 ± 19 
VO2peak (% predicted) 
Orenstein/Jones
 80 ± 19  82 ± 20 
Wattmax (W) 125 (95, 168) 130 (94, 176) 
Wattmax (% predicted) 
Godfrey
  86 ± 22  83 ± 20 
Wattmax (% predicted) 
Godfrey/Jones
  91 ± 24  90 ± 21 
HRmax (% predicted) 93 (88, 96) 92 (87, 96) 
RER 1.16 (1.10, 1.23) 1.15 (1.09, 1.23) 
VEpeak/MVVpred (%)
*
 88 (71, 104) 78 (63, 96) 
Data are mean±SD or median (interquartile range) or N (%). BMI; body mass index; CFRD, Cystic 
fibrosis related diabetes; CFTR, cystic fibrosis transmembrane conductance regulator; FEV1, 
forced expiratory volume in one second; HRmax, maximum heart rate; MVVpred, predicted 
maximum voluntary ventilation (calculated as FEV1*35); RER, respiratory exchange ratio; VEpeak, 
peak minute ventilation; VO2peak, peak oxygen consumption; Wattmax, maximum work rate. 
Percent predicted values for VO2peak were calculated using equations from Orenstein et al. (22) 
and Jones et al. (21). Data for VO2peak are shown separately according to Orenstein et al. (22) 
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and a combination of Orenstein et al. (22) and Jones et al. (21) for patients aged ≤16 and >16 
years, respectively. Wattmax % predicted values were calculated using equations from Godfrey 
et al. (23) and Jones et al. (21). Data are shown separately according to Godfrey et al. (23) and a 
combination of Godfrey et al. (23) and Jones et al. (21) for patients aged ≤16 and >16 years, 
respectively. Statistical comparisons between the two groups were performed using the 
independent t-test or the non-parametric Mann-Whitney U test or the χ
2
 test, as appropriate. 
*
P<0.05, 
†
P<0.001 significantly different between CFTR classes. 
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Table 4. Mixed models on the association between patients with two CFTR mutations in class I, 
II or III (group I-III) compared to patients with at least one mutation in class IV or V (group IV-V).  
 
 B-coefficients (95% CI’s) SE P-value 
VO2peak (% predicted)    
Age -0.14 (-0.32 to 0.04) 0.09 0.14 
Sex -1.29 (-3.46 to 0.88) 1.11 0.24 
Pseudomonas aeruginosa  -1.93 (-4.44 to 0.58) 1.28 0.13 
BMI z-score  1.78 (0.78 to 2.77) 0.51 <0.001 
FEV1 (% predicted) 0.41 (0.35 to 0.47) 0.03 <0.001 
CFTR group -0.95 (-4.18 to 2.29) 1.65 0.57 
    
Wattmax (% predicted)    
Age 0.02 (-0.19 to 0.23) 0.11 0.87 
Sex 0.23 (-2.21 to 2.66) 1.24 0.85 
Pseudomonas aeruginosa  -2.85 (-5.69 to -0.22) 1.45 0.048 
BMI z-score  1.30 (0.19 to 2.42) 0.57 0.02 
FEV1 (% predicted) 0.46 (0.40 to 0.53) 0.03 <0.001 
CFTR group -1.38 (-5.04 to 2.27) 1.86 0.46 
BMI, body mass index; CFRD, Cystic fibrosis related diabetes; FEV1, forced expiratory volume in 
one second; SE, standard error; VO2peak, peak oxygen consumption, Wattmax, maximum work 
load. The categorical variable Pseudomonas aeruginosa is coded as ‘0’ = no and ‘1’ = yes. Sex is 
coded as ‘0’ for females and ‘1’ for males. CFTR groups are coded as ‘0’ (class I-III combined) 
and ‘1’ (class IV-V combined). VO2peak and Wattmax % predicted values were calculated using 
reference equations from Orenstein et al. (22) and Godfrey et al. (23), respectively. 
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Flow chart of included patients. CFTR, cystic fibrosis transmembrane conductance regulator; CPET, 
cardiopulmonary exercise test.  
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Online Data Supplement 
 
CFTR Genotype and Maximal Exercise Capacity in Cystic Fibrosis: A Cross-sectional Study  
 
Thomas Radtke, Helge Hebestreit, Sabina Gallati, Jane E Schneiderman, Julia Braun, Daniel 
Stevens, Erik HJ Hulzebos, Tim Takken, Steven R Boas, Don S Urquhart, Larry C Lands, Sergio 
Tejero, Aleksandar Sovtic, Tiffany Dwyer, Milos Petrovic, Ryan A Harris, Chantal Karila, 
Daniela Savi, Jakob Usemann, Meir Mei-Zahav, Elpis Hatziagorou, Felix Ratjen, Susi Kriemler, 
for the CFTR-Exercise study group 
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Methods 
 
Inclusion and exclusion criteria  
 
Study centers that could provide data on at least 20 patients, aged 8 years or older who completed a maximal 
cardiopulmonary exercise test (CPET) between January 1999 and December 2014 were eligible. We excluded patients 
with missing or incomplete information on cystic fibrosis transmembrane conductance regulator (CFTR) genotype and 
those who did not achieve the criteria for a maximal effort during CPET.  
 
Cardiopulmonary exercise test (CPET) 
 
All patients performed a cycle ergometer test employing the Godfrey cycle protocol (1) or a modification thereof. Patients 
were tested during stable clinical conditions (i.e., free of pulmonary exacerbations for at least 2 weeks) and exercise tests 
were performed as part of routine annual assessments and/or exercise studies. In case of exercise studies, baseline data 
were used. The principal investigator (TR) received all CPET data from the national investigators in a coded Excel 
spreadsheet. All CPET data were checked for plausibility and, if necessary, the PI contacted the national investigators to 
confirm the plausibility of the data. Raw data files were not re-evaluated as part of this retrospective study.  
We excluded patients who did not achieve the criteria for a maximal effort during CPET: 1) a respiratory 
exchange ratio (RER) ≥1.05 for adults and ≥ 1.03 for children (2); 2) peak heart rate that reached or exceeded predicted 
peak heart rate (for children ≥195 beats.min-1 (3)), for adults based on published equations in (4)); 3) ventilation at peak 
exercise (VEpeak) exceeding estimated maximal voluntary ventilation (MVV=forced expiratory volume in 1s (FEV1) x 35) 
(5); 4) the patient achieved the predicted peak oxygen uptake (VO2peak); or 5) the patient achieved the predicted maximum 
work rate (Wattmax) (2). At least one of five criteria had to be fulfilled for the test to be considered maximal. In case of 
missing data (e.g., RER or heart rate), the respective criterion was considered as not fulfilled.  
We calculated % predicted values for VO2peak (6, 7), Wattmax (6, 8) and peak heart rate (4). Prediction equations 
for VO2peak (primary endpoint) and Wattmax (secondary endpoint) published by Orenstein et al. (7) and Godfrey et al. (8) 
were used for the final statistical models. In addition, we computed % predicted values using reference equations from 
Jones et al. (6) for VO2peak and Wattmax for patients 16 years and older.  We compared all statistical models using the Jones 
et al. (6) reference equations in combination with Orenstein et al. (7) and Godfrey et al. (8) versus Orenstein et al. (7) and 
Godfrey et al. (8) alone. 
 
Body composition  
 
Body fat (BF, in %) was calculated using age and sex-specific prediction formulas (≤ 15 years; >15 years) by Deurenberg 
et. al.(9) Lean body mass (LBM) was calculated from body weight and body fat. We did a cross-validation between 
predicted values for BF (%) and LBM (kg) with dual-energy absorptiometry (DXA) measured BF (%) and LBM (kg) 
from the Swiss cohort (39 patients with CF; 20 females) aged 15 to 39 years with a median (IQR) FEV1 of 62 (46, 75) % 
predicted)). The mean bias between predicted and measured BF was 0.20% (95% CI, -1.39 to 1.43). The mean bias 
between predicted and measured LBM was -3.32 kg (95% CI, -4.30 to -2.50).  
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Statistical analysis 
The Kolmogorov-Smirnov test was used to assess normal distribution of data. Normally distributed data were presented 
as mean±SD, data not following a normal distribution as median (inter-quartile range) or N (%). Descriptive analysis was 
performed using the independent t-test or non-parametric Mann-Whitney U test. The χ2 test was used to compare 
categorical variables among groups. Statistical comparisons among the five groups based on CFTR classes were 
performed using ANOVA or the non-parametric Kruskal-Wallis test.  
Mixed-effects models with a random intercept for each study center were used to determine associations between 
CFTR genotype-based group and VO2peak (% predicted, primary endpoint) and Wattmax (% predicted, secondary endpoint) 
and adjusted for the following predictor variables: age, sex, BMI z-score, FEV1 (% predicted) and chronic infection with 
Pseudomonas aeruginosa. Akaike’s information criterion (AIC) was used for model choice.  
 
Allometric Models 
We performed regression analysis using a multiplicative, allometric approach (10, 11) to eliminate potential effects of 
body size and pulmonary function on the relationship between CFTR genotype and VO2peak. This approach is based on the 
assumption that VO2peak is not linearly related to measures of body size, e.g. body mass M, but is proportional to power 
functions of those measures, for example M to the power of an exponent x. This approach has been used previously to 
determine predictors of VO2peak in cystic fibrosis (McFadden,  #69) patients (11). For the allometric model, we computed 
the natural logarithm (Hose,  #108) of VO2peak (primary outcome measure) and Wattmax (secondary outcome measure), 
which entered the regression as dependent variable. We considered the following covariates in the model: age, ln(weight), 
ln(height), ln(FEV1), presence of Pseudomonas aeruginosa infection and CFTR genotype. We performed two separate 
analyses with ln(VO2peak) (in L) and ln(Wattmax) (in Watt) as dependent variables. 
All statistical analyses were performed with the statistical software package SPSS version 23 (IBM Corp. 
Armont, NY, USA) and Stata statistical software version 12 (StataCorp. 2012, College Station, Texas, USA). The 
significance level was set at P<0.05. 
 
Results 
 
We contacted 32 centres in North America, Europe, Australia and Asia by email of which 17 provided data for this study. 
Fifteen centers did not participate for the following reasons: nine centers did not reply to our email request; two persons 
from two centers had no longer access to CPET data; for two centers the effort to obtain ethical approval was considered 
too demanding; one center had only treadmill CPET data available and one person at one center was not allowed to share 
CPET data due to the current personal contract. 
 
Maximal CPET 
726 /838 patients had a maximal CPET based on predefined criteria for a maximal effort. Of these patients, n=85 
achieved the peak heart rate criterion; n=604 achieved the RER criterion; n=103 achieved the VO2peak criterion; n= 179 
achieved the Wattmax criterion and n=210 achieved the VEpeak/MVVpred criterion. 
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Figure E1. Relationship between FEV1 (% predicted) and VO2peak (% predicted) in a sample of 726 patients (r=0.60).  
 
***INSERT FIGURE HERE*** 
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Supplementary Tables 
 
Table E1 Functional classification of CFTR alleles  
 
CFTR classes (I-V) 
 
CFTR nomenclature by legacy names 
 
Class I 
 
S4X, CFTRdele2,3, Q39X, E60X, 405+ 1G->A, 306delTAGA, 365-366insT, 489delC, 
547insGA, 557delT, 574delA, 621+1G->T, Y109X, 711+1G->T, Q220X, L218X, C276X, 
1154insTC, 1461ins4, 1525-1G->A, S466X, S489X, Q493X, 1677delTA, E479X, Q525X, 
1717-1G->A, G542X, G550X, R553X, E585X, 1898+1G->A, 1259insA, 2183AA->G, 
R709X, 2347delG, 2184insA, E822X, R785X, Q781X, 2896insAG, W882X, 2991del32, 
3120+1G->A, 3121-1G->A, V1108L, E1104X, R1070Q, Y1092X, E1104X, R1162X, 
3791delC, 3659delC, 3724delG, 3732delA, 3876delA, 3905insT, R1283M, W1274X, 
W1282X, 4040delA, 4021insT, CFTRdele10, CFTRdele19-21, CFTRdele16-18, 
CFTRdele14b-17b, c.3874-1G>A, 1154insTC  
 
Class II 
 
G85E, G178R, F508del, I507del, L1077P, M1101K, R1162X, N1303K 
 
 
Class III 
 
 
M1V, G551D, S549R, R560T, S549N, Y569D, H609R, H1085R, S1251N 
 
Class IV 
 
P5L, P67L, R74W, G126D, I148T, R117H, D192G, L206W, V232D, L320V, L365P, 
R334W, Q359K/T360K, R347P, T338I, N369Y, V562I, 1717- 8G->A, Y914C, L997F, 
D1152H, S1235R, S18I, S898R, A457P, G567A, V109C, G1244V 
 
 
Class V 
 
 
1249-30delAT, A455E, 1811+1.6kbA->G, 2789+5G>A, 2789+ 5G>A, 3272-26A->G, 
3849+10kbC->T, 5T, 5T-12TG, 5T-13TG  
 
CFTR, cystic fibrosis transmembrane conductance regulator.  
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Table E2 Mixed linear models on the association between patients with two CFTR mutations in class I, II or III 
compared with patients with at least one mutation in class IV or V.  
 
ln(VO2peak) (L) B-coefficients (95% CI’s) SE P-value 
Age -0.00 (-0.00 to 0.00) 0.15 0.119 
Sex 0.16 (0.14 to 0.19) 0.01 <0.001 
ln(weight) (kg) 0.37 (0.26 to 0.48) 0.06 <0.001 
ln(height) (m) 0.50 (0.16 to 0.84) 0.17 0.004 
ln(FEV1) (L) 0.39 (0.34 to 0.44) 0.02 <0.001 
Pseudomonas aeruginosa  -0.02 (-0.05 to 0.01) 0.02 0.171 
CFTR class  -0.16 (-0.56 to 0.02) 0.02 0.449 
    
ln(Wattmax) (W)    
Age -0.00 (-0.00 to 0.00) 0.00 0.192 
Sex 0.14 (0.11 to 0.17) 0.15 <0.001 
ln(weight) (kg) 0.30 (0.19 to 0.42) 0.06 <0.001 
ln(height) (m) 0.95 (0.59 to 1.32) 0.19 <0.001 
ln(FEV1) (L) 0.39 (0.34 to 0.44) 0.03 <0.001 
Pseudomonas aeruginosa  -0.03 (-0.07 to -0.01) 0.02 0.041 
CFTR class  -0.02 (-0.07 to 0.21) 0.02 0.308 
CFRD, Cystic fibrosis related diabetes; CFTR, cystic fibrosis transmembrane conductance regulator; FEV1, forced 
expiratory volume in one second; ln, natural logarithm; SE, standard error; VO2peak, peak oxygen consumption, Wattmax, 
maximum work load. The categorical variable Pseudomonas aeruginosa infection is coded as ‘0’ = no and ‘1’ = yes. Sex 
is coded as ‘0’ for females and ‘1’ for males. CFTR groups are coded as ‘0’ for CFTR classes I-III and ‘1’ for CFTR 
classes IV-V. 
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Table E3 Clinical characteristics and cardiopulmonary exercise testing data between patients with two CFTR mutations 
in class I, II or III compared with patients with at least one mutation in class IV or V. Data are shown for a subpopulation 
of patients with preserved lung function (FEV1 ≥ 80% predicted) and nutritional status (BMI z-score ≥ 50
th
 percentile).  
 
Variable CFTR classes I-III CFTR classes IV-V 
N 138 30 
CFTR modulator therapy (N, %) 2 (1) 0 (0) 
Age 14.4 (11.6, 17.7) 15.2 (11.2, 19.0) 
Sex, (% female) 71 (51) 12 (40) 
CFRD, (N, %) 8 (6) 0 (0) 
Pancreatic insufficiency, (N, %)† 128 (93) 6 (20) 
Pseudomonas aeruginosa, (N, %)
*
 48 (36) 3 (10) 
BMI z-score*  0.54 (0.24, 0.88) 1.10 (0.32, 1.80) 
Body fat (%) 21.3 ± 5.1 22.4 ± 6.1 
Lean body mass (kg)
*
 41.4 (31.9, 49.5) 48.4 (35.5, 70.0) 
FEV1 (% predicted) 94 (86, 105) 95 (85, 101) 
VO2peak (L.min
-1
) 1.9 (1.5, 2.5) 2.2 (1.6, 2.9) 
VO2peak (% predicted) 
Orenstein 91 ± 16 89 ± 17 
VO2peak (% predicted) 
Orenstein/Jones 92 ± 17 88 ± 17 
Wattmax (W) 134 (100, 173) 150 (104, 206) 
Wattmax (% predicted) 
Godfrey
 95 ± 19  95 ± 21 
Wattmax (% predicted) 
Godfrey/Jones
 100 ± 23  99 ± 24 
HRmax (% predicted) 95 (91, 99) 94 (88, 97) 
RER 1.17 (1.11, 1.24) 1.13 (1.09, 1.22) 
VEpeak/MVVpred (%)
* 77 (67, 91) 68 (56, 80) 
Data are mean±SD or median (interquartile range) or N (%). BMI; body mass index; CFRD, Cystic fibrosis related 
diabetes; CFTR, cystic fibrosis transmembrane conductance regulator; FEV1, forced expiratory volume in one second; 
HRmax, maximum heart rate; MVVpred, predicted maximum voluntary ventilation (calculated as FEV1*35); RER, 
respiratory exchange ratio; VEpeak, peak minute ventilation; VO2peak, peak oxygen consumption; Wattmax, maximum work 
rate. Percent predicted values for VO2peak were calculated using equations from Orenstein et al. (7) and Jones et al. (6). 
Data for VO2peak are shown separately according to Orenstein et al. (7) and a combination of Orenstein et al. (7) and Jones 
et al. (6) for patients aged ≤16 and >16 years, respectively. Wattmax % predicted values were calculated using equations 
from Godfrey et al. (8) and Jones et al. (6). Data are shown separately according to Godfrey et al. (8) and a combination 
of Godfrey et al. (8) and Jones et al. (6) for patients aged ≤ 16 and >16 years, respectively. Statistical comparisons 
between the two groups were performed using the independent t-test the non-parametric Mann-Whitney U test or the χ2 
test, as appropriate. *P<0.05, †P<0.001 significantly different between CFTR classes. 
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Table E4. Mixed models on the association between patients with two CFTR mutations in class I, II or III (group I-III) 
compared to patients with at least one mutation in class IV or V (group IV-V). Data are shown for a subpopulation of 
patients with preserved FEV1 (≥ 80% predicted) and nutritional status (BMI z-score ≥ 50
th
 percentile). 
 
 B-coefficients (95% CI’s) SE P-value 
VO2peak (% predicted)    
Age 0.09 (-0.35 to 0.54) 0.23 0.681 
Sex -2.95 -7.86 to 1.96) 2.51 0.239 
Pseudomonas aeruginosa  1.47 (-4.39 to 7.34) 2.99 0.622 
BMI z-score  0.77 (-3.4 to 3.97) 2.13 0.717 
FEV1 (% predicted) 0.27 (0.05 to 0.51) 0.12 0.016 
CFTR group -5.08 (-14.29 to 4.12) 4.70 0.279 
    
Wattmax (% predicted)    
Age 0.86 (0.35 to 1.37) 0.26 0.001 
Sex -1.48 (-6.51 to 3.55) 2.57 0.565 
Pseudomonas aeruginosa  0.68 (-5.47 to 6.83) 3.14 0.829 
BMI z-score  -1.76 (-6.01 to 2.49) 2.17 0.416 
FEV1 (% predicted) 0.28 (0.05 to 0.51) 0.11 0.019 
CFTR group -2.07 (-11.95 to 7.81) 5.04 0.618 
BMI, body mass index; FEV1, forced expiratory volume in one second; SE, standard error; VO2peak, peak oxygen 
consumption, Wattmax, maximum work load. VO2peak and Wattmax % predicted values were calculated using reference 
equations from Orenstein et al. (7) and Godfrey et al. (8), respectively. The categorical variable Pseudomonas aeruginosa 
is coded as ‘0’ = no and ‘1’ = yes. Sex is coded as ‘0’= female and ‘1’ = male. CFTR groups are coded as ‘0’ (class I-III 
combined) and ‘1’ (class IV-IV combined). 
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Table E5 Clinical characteristics and cardiopulmonary exercise testing data between patients with two CFTR mutations 
in class I, II or III compared with patients with at least one mutation in class IV or V. Data are shown for a subpopulation 
of patients with moderate to severe lung function impairment (FEV1 ≤ 60% predicted).  
 
Variable CFTR classes I-III CFTR classes IV-V 
N 160 19 
CFTR modulator therapy (N, %) 2 (1) 1 (5) 
Age 20.7 (16.5, 28.0) 28.0 (22.0, 36.0) 
Sex, (% female)* 59 (37) 13 (68) 
CFRD, (N, %) 35 (22) 3 (16) 
Pancreatic insufficiency, (N, %)† 149 (95) 6 (32) 
Pseudomonas aeruginosa, (N, %) 122 (79) 15 (79) 
BMI z-score -0.62 (-1.54, 0.53) -0.25 (-1.03, 0.28) 
Body fat (%)
†
 17.1 ± 6.1 22.9 ± 6.6 
Lean body mass (kg) 44.2 (36.4, 52.9) 43.0 (38.4, 48.4) 
FEV1 (% predicted) 46 (37, 53) 45 (34, 56) 
VO2peak (L.min
-1
) 1.6 (1.2, 2.0) 1.3 (1.2, 1.7) 
VO2peak (% predicted) 
Orenstein 62 ± 15 59 ± 13 
VO2peak (% predicted) 
Orenstein/Jones 63 ± 15 65 ± 15 
Wattmax (W)
* 120 (90, 15) 90 (80, 112) 
Wattmax (% predicted)
 †
 
Godfrey
 70 ± 19  60 ± 15 
Wattmax (% predicted) 
Godfrey/Jones
 77 ± 21  72 ± 16 
HRmax (% predicted)
 * 94 (84, 94) 87 (81, 92) 
RER 1.14 (1.07, 1.21) 1.14 (1.05, 1.23) 
VEpeak/MVVpred (%) 111 (97, 125) 101 (91, 117) 
Data are mean±SD or median (interquartile range) or N (%). BMI; body mass index; CFRD, Cystic fibrosis related 
diabetes; CFTR, cystic fibrosis transmembrane conductance regulator; FEV1, forced expiratory volume in one second; 
HRmax, maximum heart rate; MVVpred, predicted maximum voluntary ventilation (calculated as FEV1*35); RER, 
respiratory exchange ratio; VEpeak, peak minute ventilation; VO2peak, peak oxygen consumption; Wattmax, maximum work 
rate. Percent predicted values for VO2peak were calculated using equations from Orenstein et al. (7) and Jones et al. (6). 
Data for VO2peak are shown separately according to Orenstein et al. (7) and a combination of Orenstein et al. (7) and Jones 
et al. (6) for patients aged ≤16 and >16 years, respectively. Wattmax % predicted values were calculated using equations 
from Godfrey et al. (8) and Jones et al. (6). Data are shown separately according to Godfrey et al. (8) and a combination 
of Godfrey et al. (8) and Jones et al. (6) for patients aged ≤ 16 and >16 years, respectively. Statistical comparisons 
between the two groups were performed using the independent t-test the non-parametric Mann-Whitney U test or the χ2 
test, as appropriate. *P<0.05, †P<0.001 significantly different between CFTR classes. 
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Table E6. Mixed models on the association between patients with two CFTR mutations in class I, II or III (group I-III) 
compared to patients with at least one mutation in class IV or V (group IV-V). Data are shown for a subpopulation of 
patients with severe lung function impairment (FEV1 ≤ 60% predicted). 
 
 B-coefficients (95% CI’s) SE P-value 
VO2peak (% predicted)    
Age -0.40 (-0.63 to -0.18) 0.11 <0.001 
Sex -1.20 (-4.71 to 2.31) 1.79 0.502 
Pseudomonas aeruginosa  -2.15 (-6.42 to 2.11) 2.18 0.322 
BMI z-score  1.46 (0.18 to 2.74) 0.65 0.025 
FEV1 (% predicted) 0.73 (0.57 to 0.89) 0.08 <0.001 
CFTR group 0.42 -5.4 to 6.3) 2.98 0.887 
    
Wattmax (% predicted)    
Age -0.27 (-0.61 to 0.06) 0.17 0.114 
Sex 1.25 (-3.73 to 6.23) 2.54 0.623 
Pseudomonas aeruginosa  -4.32 (-10.39 to 1.73) 3.09 0.162 
BMI z-score  1.02 (-0.79 to 2.82) 0.92 0.270 
FEV1 (% predicted) 0.66 (0.42 to 0.89) 0.12 <0.001 
CFTR group -5.14 (-13.51 to 3.22) 4.27 0.228 
BMI, body mass index; FEV1, forced expiratory volume in one second; SE, standard error; VO2peak, peak oxygen 
consumption, Wattmax, maximum work load. VO2peak and Wattmax % predicted values were calculated using reference 
equations from Orenstein et al. (7) and Godfrey et al. (8), respectively. The categorical variable Pseudomonas aeruginosa 
is coded as ‘0’ = no and ‘1’ = yes. Sex is coded as ‘0’= female and ‘1’ = male. CFTR groups are coded as ‘0’ (class I-III 
combined) and ‘1’ (class IV-IV combined). 
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 Table E7 Clinical characteristics and cardiopulmonary exercise testing data according to the class of second CFTR mutation in patients with at least one copy of 
the F508del mutation.  
 
 CFTR class II/I CFTR class II/II CFTR class II/III CFTR class II/IV CFTR class II/V 
N 154 394 35 43 27 
Age 15.4 (12.7, 20.0) 16.4 (13.0, 22.0) 17.8 (13.2, 25.6) 16.9 (12.0, 22.0) 16.4 (13.7, 24.0) 
Sex (% female) 81 (53) 161 (41) 15 (43) 20 (47) 9 (33) 
CFRD, (N, %) 14 (9) 50 (13)  3 (9) 1 (2) 0 (0) 
Pancreatic insufficiency (N, %)
†
 147 (95)
 
 371 (95)
 
 30 (88)
 
 8 (22) 8 (30) 
Pseudomonas aeruginosa (N, %)* 79 (52) 213 (55) 18 (53) 17 (39) 7 (26) 
BMI (kg.m
-2
)
*
 19.2 (17.2, 21.4) 19.3 (17.4, 21.6) 21.6 (17.5, 24.7) 20.6 (18.8, 22.1) 22.6 (19.2, 25.1) 
BMI z-score -0.37 (-1.02, 0.33) -0.25 (-0.94, 0.41) 0.35 (-0.49, 1.04) -0.25 (-0.77, 0.63) 0.04 (-0.73, 0.68) 
Body fat (%)
*
  18.5 ± 57  18.0 ± 6.0  20.1 ± 5.8  20.5 ± 6.4  20.9 ± 6.3 
Lean body mass (kg)
 *
 41.0 (33.3, 49.4) 41.3 (32.7, 50.7) 45.2 (34.6, 55.3) 43.5 (35.9, 52.8) 48.7 (41.9, 61.7) 
FEV1 (% predicted) 82 (64, 96) 78 (58, 93) 78 (49, 90) 85 (72, 96) 82 (63, 99) 
VO2peak (L.min
-1
) 1.75 (1.4, 2.2) 1.75 (1.4, 2.3) 1.85 (1.3, 2.2) 1.89 (1.5, 2.4) 1.96 (1.4, 2.5) 
VO2peak (% predicted) 
Orenstein  80 ± 17  79 ± 20  76 ± 23  85 ± 18  74 ± 19 
VO2peak (% predicted) 
Orenstein/Jones  81 ± 17  80 ± 20  78 ± 22  86 ± 19  76 ± 19 
Wattmax (W) 123 (92, 161) 129 (100, 175) 135 (97, 172) 117 (93, 175) 136 (112, 195) 
Wattmax (% predicted) 
Godfrey  85 ± 22  87 ± 22  85 ± 27  85 ± 20  82 ± 18 
Wattmax (% predicted) 
Godfrey/Jones  91 ± 25  92 ± 23  91 ± 28  91 ± 21  88 ± 18 
HRmax (% predicted) 93 (89, 96) 93 (88, 97) 93 (87, 98) 92 (86, 95) 92 (87, 96) 
RER 1.14 (1.11, 1.20) 1.16 (1.09, 1.24) 1.16 (1.09, 1.24) 1.14 (1.09, 1.20) 1.17 (1.08, 1.23) 
VEpeak/MVVpred (%)
* 83 (66, 100) 89 (73, 105) 95 (72, 118) 75 (65, 96) 78 (60, 89) 
Data are mean±SD or median (interquartile range) or N (%). BMI; body mass index; CFRD, Cystic fibrosis related diabetes; FEV1, forced expiratory volume in one second; HRmax, maximum heart 
rate; MVVpred, predicted maximum voluntary ventilation (calculated as FEV1*35); RER, respiratory exchange ratio; VEpeak, peak minute ventilation; VO2peak, peak oxygen consumption; Wattmax, 
maximum work rate. Percent predicted values for VO2peak were calculated using equations from Orenstein et al. (7) and Jones et al. (6). Data for VO2peak are shown separately according to Orenstein 
et al. (7) and a combination of Orenstein et al. (7) and Jones et al. [6] for patients aged ≤16 and >16 years, respectively. Wattmax % predicted values were calculated using equations from Godfrey et 
al. (8) and Jones et al. (6). Data are shown separately according to Godfrey et al. (8) and a combination of Godfrey et al. (8) and Jones et al. (6) for patients aged ≤ 16 and >16 years, respectively. 
Statistical comparisons between different CFTR classes were performed using ANOVA or the non-parametric Kruskal-Wallis test or χ2 test for categorical variables. *P<0.05; † P<0.001 significantly 
different between CFTR classes.
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Table E8 Mixed models on the association between class of second CFTR mutation and maximal exercise capacity in 
patients with at least one copy of the F508del mutation.  
 
 B-coefficients (95% CI’s) SE P-value 
VO2peak (% predicted)     
Age -0.12 (-0.32 to 0.07) 0.10 0.207 
Sex -1.06 (-3.34 to 1.22) 1.16 0.363 
BMI z-score  2.05 (0.97 to 3.11) 0.54 <0.001 
FEV1 (% predicted) 0.42 (0.36 to 0.48) 0.03 <0.001 
Pseudomonas aeruginosa  -2.73 (-5.35 to -0.11) 1.34 0.041 
CFTR class II/I -1.42 (-4.19 to 1.35) 1.41 0.315 
CFTR class II/II - - - 
CFTR class II/III -2.56 (-7.67 to 2.55) 2.61 0.327 
CFTR class II/IV 2.54 (-2.16 to 7.25) 2.40 0.290 
CFTR class II/V -8.24 (-14.53 to -2.99) 2.94 0.003 
    
Wattmax (% predicted)     
Age 0.04 (-0.19 to 0.27) 0.12 0.709 
Sex 1.12 (-1.50 to 3.74) 1.34 0.403 
BMI z-score  1.30 (0.08 to 2.51) 0.62 0.036 
FEV1 (% predicted) 0.47 (0.40 to 0.54) 0.03 <0.001 
Pseudomonas aeruginosa  -3.11 (-6.14 to -0.09) 1.54 0.044 
CFTR class II/I -1.08 (-4.27 to 2.11) 1.63 0.466 
CFTR class II/II - - - 
CFTR class II/III -0.08 (-6.02 to 5.86) 3.03 0.978 
CFTR class II/IV 0.03 (-5.39 to 5.64) 2.77 0.990 
CFTR class II/V -7.59 (-14.21 to -0.95) 3.38 0.025 
CFRD, Cystic fibrosis related diabetes; CFTR, cystic fibrosis transmembrane conductance regulator; FEV1, forced 
expiratory volume in one second; SE, standard error; VO2peak, peak oxygen consumption, Wattmax, maximum work load. 
VO2peak and Wattmax % predicted values were calculated using reference equations from Orenstein et al. (7) and Godfrey 
et al. (8), respectively. The categorical variable Pseudomonas aeruginosa infection is coded as ‘0’ = no and ‘1’ = yes. Sex 
is coded as ‘0’ for females and ‘1’ for males. CFTR classes were coded as class II/II = 1; class I/II = 2; class II/III = 3; 
class II/IV = 4 and class II/V =5. The CFTR class II/II was chosen as reference class.   
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Table E9 Mixed models on the association between class of second CFTR mutation and maximal exercise capacity in 
patients with at least one copy of the F508del mutation.  
 
 B-coefficients (95% CI’s) SE P-value 
ln(VO2peak) (L)    
Age -0.00 (-0.00 to 0.00) 0.00 0.123 
Sex 0.17 (0.14 to 0.20) 0.02 <0.001 
ln(weight) (kg) 0.38 (0.26 to 0.47) 0.06 <0.001 
ln(height) (m) 0.48 (0.12 to 0.85) 0.19 0.009 
ln(FEV1) (L) 0.40 (0.35 to 0.45) 0.03 <0.001 
Pseudomonas aeruginosa  -0.03 (-0.06 to 0.00) 0.02 0.083 
CFTR class II/I -0.01 (-0.04 to 0.02) 0.02 0.624 
CFTR class II/II - - - 
CFTR class II/III -0.05 (-0.11 to 0.01) 0.03 0.133 
CFTR class II/IV 0.03 (-0.03 to 0.09) 0.03 0.353 
CFTR class II/V -0.12 (-0.19 to -0.05) 0.04 0.001 
    
ln(Wattmax) (W)    
Age -0.00 (-0.00 to 0.00) 0.00 0.363 
Sex 0.15 (0.12 to 0.18) 0.02 <0.001 
ln(weight) (kg) 0.31 (0.18 to 0.43) 0.07 <0.001 
ln(height) (m) 0.92 (0.53 to 1.32) 0.20 <0.001 
ln(FEV1) (L) 0.40 (0.35 to 0.45) 0.03 <0.001 
Pseudomonas aeruginosa  -0.04 (-0.07 to -0.00) 0.02 0.049 
CFTR class II/I -0.01 (-0.05 to 0.02) 0.02 0.448 
CFTR class II/II - - - 
CFTR class II/III -0.04 (-0.10 to 0.03) 0.04 0.313 
CFTR class II/IV -0.01 (-0.07 to 0.06) 0.03 0.826 
CFTR class II/V -0.10 (-0.18 to -0.02) 0.04 0.014 
CFRD, Cystic fibrosis related diabetes; CFTR, cystic fibrosis transmembrane conductance regulator; FEV1, forced 
expiratory volume in one second; ln, natural logarithm; SE, standard error; VO2peak, peak oxygen consumption, Wattmax, 
maximum work load. The categorical variable Pseudomonas aeruginosa infection is coded as ‘0’ = no and ‘1’ = yes. Sex 
is coded as ‘0’ for females and ‘1’ for males. CFTR classes were coded as class II/II = 1; class I/II = 2; class II/III = 3; 
class II/IV = 4 and class II/V =5. The CFTR class II/II was chosen as reference class.   
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Relationship between FEV1 (% predicted) and VO2peak (% predicted) in a sample of 726 patients (r=0.60). 
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